Despite the existence of efficient vaccines, human HBV still infects an estimated 400 million people worldwide, who represent an important reservoir for viral dissemination [1] . The major complications of chronic HBV infection are the development of liver cirrhosis and hepatocellular carcinoma [2] . Indeed, chronic HBV carriers have a 100-fold higher risk of developing hepatocellular carcinoma, and approximately 80% of cases of hepatocellular carcinoma are linked to HBV [2] . HBV is a small enveloped DNA virus member of the Hepadnavirus family, and its genome consists of a relaxed, circular, partially double-stranded 3.2 kb DNA molecule. Five unspliced messenger transcripts of 3.5 (short and long), 2.4, 2.1 and 0.8 kb in size are synthesized from the HBV genome and encode the capsid, envelope, polymerase and transactivator X viral proteins, respectively [3] . A 3.5 kb short pregenomic messenger RNA is also involved in the HBV replication cycle via its reverse transcription, which occurs in core particles [3] . The current treatments available for HBV chronic carriers, using interferon (IFN)-α or nucleoside/nucleotide analogues, are not effective in all patients [3] . Longterm IFN-α treatment is only effective in one-third of patients and causes significant side effects, such as fatigue, fever, muscle aches, bone marrow suppression, psychosis and autoimmune conditions [4] . As for treatment with nucleoside/nucleotide analogues, data support an association between durable HBV DNA suppression of replication and an improvement in both hepatic fibrosis and hepatic decompensation [5] . However, the long-term use of nucleoside/ nucleotide analogues might induce the emergence of drugresistant HBV strains harbouring mutations within
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Throughout the natural history of HBV infection, both innate and adaptive immune responses are involved in the clearance of HBV from infected hepatocytes. It has been suggested that HBV is cleared through the destruction of infected hepatocytes by cytotoxic T-lymphocytes (CTLs) [8] . It has also been reported that HBV replication could be regulated by a process that is mediated by inflammatory cytokines, such as IFN-γ and tumour necrosis factor (TNF)-α, which are secreted by CTLs following antigen recognition in the liver [8, 9] . IFN-γ is a type-II IFN and is mainly expressed by natural killer and natural killer T-cells as part of the innate immune response, and by CD4 + and CD8 + CTL cells once antigen-specific immunity has developed [10] . IFN-γ is endowed with antiviral, immunoregulatory and anti-tumour properties by modulating the transcription of immunologically relevant genes, triggering a variety of physiological and cellular responses [10] .
The antiviral activity of IFN-γ against HBV replication has been demonstrated in HBV transgenic and hepatocyte cell lines [8, [11] [12] [13] . Experimental animal models for HBV have demonstrated that the induction of IFN-γ and TNF-α represents an important antiviral event. Indeed, in HBV transgenic mice, the elimination of HBV replication by IFN-γ and TNF-α is mediated by a non-cytopathogenic mechanism [14] . Furthermore, microarray analysis of the liver of HBV-infected chimpanzees revealed that IFN-γ and its stimulated genes are major players in viral resolution [15] . Several studies have demonstrated that HBV replication is blocked by the expression of IFN-γ at a post-transcriptional step [16] [17] [18] . And similar to type-I IFN, the antiviral mechanism of IFN-γ that is involved in inhibiting HBV replication results from disruption of the assembly of viral pregenomic RNA-containing capsids [9] . In parallel to its HBV antiviral activity, it has been reported that in cells constitutively expressing HBV, IFN-γ selectively inhibits HBV-mediated nuclear factor-κB activation through the nuclear localization of nuclear factor-κB-inducing kinase [13] . IFN-γ has been used in a series of studies to treat HBV infections, either alone or in combination with other IFNs and with varying success [19] [20] [21] [22] .
The thermal stability of human IFN-γ is very poor, and degraded forms of IFN-γ might have a weaker potency and cause severe adverse effects if they are injected [23] [24] [25] . It would therefore be interesting to obtain a novel recombinant IFN-γ endowed with enhanced thermostability. However, methods to select proteins with increased stability are used very rarely [26, 27] . It was shown recently that thermophilic bacteria, such as Thermus thermophilus, can be employed as a host for the selection of thermoresistant proteins [26] . This method is based on a fusion construct comprising the protein of interest and a thermostable antibiotic resistance reporter [26, 27] . In the present study, we combined the Massive Mutagenesis ® and the thermoresistant selection (THR™) technologies in order to select human IFN variants with increased thermostability (Figure 1 ) [28] [29] [30] . Of the selected human IFN-γ variants, one displayed a change at amino acid 63 from a serine to a cysteine residue (S63C IFN-γ). This prompted us to investigate whether this S63C IFN-γ thermostable variant could activate the IFN-γ signalling pathway, and to evaluate its antiviral efficacy against HBV replication.
Methods

Cell cultures
HeLa cells (American Type Culture Collection [ATCC] CCL-2) and human hepatoma cell line 2.2.15 (HepG2.2.15) constitutively expressing HBV [31] were grown in Dulbecco's modified Eagle's medium supplemented with GlutaMAX™ (Invitrogen, Cergy Pontoise, France). COS-7 cells (ATCC CRL-1651) were grown in Iscove's modified Dulbecco's medium supplemented with GlutaMAX™. Media were supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin and 0.1 mg/ml streptomycin (Invitrogen).
IFN production
The wt and S63C IFN-γ were cloned into the pORF plasmid (Invitrogen) containing an elongation factor-1α hybrid promoter and an SV40 polyadenylation termination signal, as previously described [32] . COS-7 cell transfections were carried out in 24-well plates using 50 ng of the pORF-IFN-γ plasmids and JetPEI™ (Polyplus Transfection, Strasbourg, France). After 24 h, the cells were washed and 500 µl of medium containing 10% of fetal bovine serum was added. After a further 48 h, the supernatants were harvested and stored at -20°C. IFN-γ was purified as previously described and its concentration was determined using a commercial ELISA kit KHC4021 (CliniSciences, Montrouge, France).
Western blot analyses
IFN-γ samples were heated at 65°C for 5 min in reducing buffer (50 mM Tris-HCl, pH 6.8, 2% sodium dodecyl sulfate, 12.5% glycerol, 0.1% bromophenol blue and 2% mercaptoethanol), then subjected to SDS-PAGE (15%) and transferred onto an Immobilon-P membrane (Millipore, Saint-Quentin en Yvelines, France). This membrane was probed for 1 h at 37°C with a polyclonal rabbit anti-IFN-γ (1:5000; Abcam, Paris, France) in 5% non-fat milk, revealed with a peroxidase-conjugated goat anti-rabbit immunoglobulin G (Bio-Rad, Marnes la Coquette, France) for 1 h at 37°C and developed using an enhanced chemiluminescence system (ECL™; Amersham-GE Healthcare, Orsay, France).
IFN activity assays
HeLa cells were transfected using pGAS-Luciferase (Stratagene-Agilent Technologies, Massy, France) and JetPEI™. IFN-γ (1 ng/ml) was preincubated for 10, 20 or 30 min at 59°C to be added for 18 h to the culture. The cells were lysed and assayed for firefly activity according to the instructions (Promega, Charbonnières, France). Firefly luciferase light emission was measured using a FLX800™ luminometer (Bio-TEK instruments, Colmar, France).
HepG2.2.15 cells were seeded onto 12-well plates at a density of 0.2×10 6 cells/well and transfected the next day using Exgen 500 transfection reagent (Fermentas, Saint Rémy-lès-Chevreuse, France) with pGAS-Luciferase and pRenilla-Luc (Promega) according to manufacturer's instructions. At 1 day post-transfection, the cells were treated with wt or S63C IFN-γ (1 ng/ml) for 18 h. The cells were then lysed and assayed for firefly and Renilla luciferase activities according to the instructions The cells were seeded onto 6-well plates and treated with or without 1 or 10 ng/ml of wt or S63C IFN-γ. At 5 days post-plating, intracellular HBV DNA was purified and analysed by Southern blotting, as previously described [33] . Intracellular HBV DNA levels were also quantified by real-time PCR using the LightCycler™ system (Roche Applied Science, Meylan, France), as previously described [34] . To normalize HBV DNA quantification, β-globin amplification was performed using the LightCycler β-globin Control Kit (Roche Diagnostics, Meylan, France) on genomic DNA extracted from HepG2.2.15 cells treated or not with IFN-γ (Qiablood extraction kit; Qiagen, Courtaboeuf, France). The experiments were carried out in duplicate and repeated three times. Statistical analyses of the data were performed using a paired Student's t-test.
Results
Characterization of the S63C IFN-γ mutant
A genetic approach to the selection of human IFN-γ mutants produced a higher level of thermostability compared with the parental protein that had previously been developed (Figure 1 ) [32] . The sequence of one of these variants showed that the mutation had changed the serine residue at amino acid 63 to a cysteine (S63C IFN-γ). Because of the cysteine mutation, the native conformation of S63C IFN-γ protein could be maintained at 70°C, thus providing a thermoresistant phenotype. This individual mutation was then introduced into the IFN-γ coding gene and expressed in COS-7 cells [32] .
Proper glycosylation is important to many biological processes, such as protein folding, stability, targeting and clearance [35] . The IFN-γ molecule contains two N-glycosylation sites at residues 25 and 97, which, in addition to a non-glycosylated form, give rise to singleor double-glycosylated forms. In order to investigate the glycosylation pattern of purified S63C IFN-γ protein, a western blot was performed. A similar pattern of non-glycosylation and glycosylation was observed for both wt and S63C IFN-γ ( Figure 2A ). We therefore assayed in vitro the thermoresistance of S63C IFN-γ to preincubation at 59°C for 10-30 min ( Figure 2B ). Residual IFN-γ activity was measured from the ability of wt and S63C IFN-γ to activate the 'gamma-activated site' using luciferase as the reporter. As expected, and in contrast to wt IFN-γ, preheating only exerted a minor effect on S63C IFN-γ activity, indicating that this mutant is better stabilized than wt IFN-γ at 59°C. Our results showed that S63C IFN-γ displayed a half-life that was 10× longer than that of the wt IFN-γ molecule.
It is well known that IFN-γ is biologically unstable under physiological conditions and is cleared rapidly from the bloodstream following administration in vivo. The mouse model was used to determine the biological stability of S63C IFN-γ. Mice were injected intravenously with wt or S63C IFN-γ, and serum IFN-γ levels were measured between 6 and 72 h after injection ( Figure 2C ). S63C IFN-γ and wt IFN-γ have a half-life of 13.6 and 7.43 h, respectively; thus, S63C IFN-γ displayed a greater stability than wt IFN-γ, its half-life being increased by 1.8-fold. This study demonstrated that wt IFN-γ is cleared from the plasma of mice more rapidly than S63C IFN-γ with clearance values of 1.83 ml/h/g and 0.58 ml/h/g, respectively. The area under the curve (AUC) increased from 57.5 pg•h/ml for the wt IFN-γ protein to 1,662.1 pg•h/ml for the S63C IFN-γ mutant.
Antiviral efficacy of S63C IFN-γ against HBV replication
In order to determine the effect of S63C IFN-γ against HBV replication, a cell line constitutively expressing HBV (HepG2.2.15) was used. These cells are able to express HBV replicative intermediates and secrete the HBV virion. Using this cell line, it had previously been demonstrated that IFN-γ was able to reduce HBV replication levels, but only after 4 days of treatment [13] .
We therefore estimated the levels of viral replication after 4 days of treatment with IFN-γ.
It had previously been reported that commercially available recombinant human IFN-γ induces cell death by apoptosis in HepG2.2.15 cells [36] . For this reason, we first assessed the cytotoxicity and activity of wt and S63C IFN-γ molecules on HepG2.2.15 cells. Cells were treated daily for 4 days with 1 or 10 ng/ml of IFN-γ, and the viability of remaining cells was checked by MTT assays (Figure 3A) . HepG2.2.15 cell viability was not reduced by either wt or S63C IFN-γ treatment. This indicates that at these IFN-γ concentrations, no adverse effects on cell viability were observed for HepG2.2.15 cells. We next assayed in HepG2.2.15 cells the ability of the S63C IFN-γ mutant molecule to activate the 'gamma activated site' using luciferase as the reporter. As shown in Figure 3B , wt and S63C IFN-γ displayed a similar capacity to activate the IFN-γ pathway.
The ability of wt or S63C IFN-γ treatment to inhibit HBV replication was then analysed using the real-time PCR quantification of intracellular encapsidated HBV DNA. Similar to wt and S63C IFN-γ, reductions of approximately 43% and 54% of HBV genome-containing nucleocapsids were observed at IFN-γ concentrations of 1 or 10 ng/ml, respectively ( Figure 4B ). Southern blot analyses using an HBV-specific probe to detect intracellular HBV genome-containing nucleocapsids, confirmed the antiviral capacity of wt and S63C IFN-γ. Indeed, a dose-dependent reduction in intracellular HBV genome-containing nucleocapsids was observed ( Figure 4A ).
We next investigated the effect of S63C IFN-γ thermostability on its ability to inhibit HBV replication more efficiently. To achieve this, HepG2.2.15 cells were treated with 1 and 10 ng/ml each of wt or S63C IFN-γ preincubated at 60°C for 10 min. Realtime PCR quantification of intracellular encapsidated HBV DNA revealed a significantly greater reduction of HBV DNA in S63C IFN-γ-treated cells than in wt IFN-γ-treated cells ( Figure 4C ). The levels of HBV DNA were reduced approximately 30% and 20% by S63C IFN-γ or wt IFN-γ, respectively, at a concentration of 1 ng/ml (P=0.02) and approximately 40% and 30% by S63C IFN-γ or wt IFN-γ, respectively, at a concentration of 10 ng/ml (P=0.05). These results indicate that the thermostability of S63C IFN-γ was associated with persistent antiviral capacity against HBV replication.
Discussion
IFN-γ induces numerous distinct cellular programmes through its transcriptional control of a large number of genes that might participate in IFN-γ-induced antiviral mechanisms [10] . Although the relationship between IFN-γ and fibrogenesis remains unclear [37] , a randomized multicentre trial of IFN-γ in patients with HBV infection and biopsy-proven hepatic fibrosis found that treatment with IFN-γ improved fibrosis scores, most probably by antagonizing profibrogenic transforming growth factor-β [38] .
The poor stability of IFN-γ means that it is difficult to use as a human therapeutic agent, and most side effects and adverse events are dose-related [39] . The data obtained during this study showed that a single amino acid replacement could increase the thermostability of IFN-γ molecules. Indeed, in vitro, the half-life of the thermostability of S63C IFN-γ was increased by approximately 10-fold, whereas in vivo, its pharmacokinetic parameters (half-life and clearance) were improved. Furthermore, wt and S63C IFN-γ display a similar ability to activate the IFN-γ pathway. Our results underline the importance of cysteine residues to the thermal stability of human protein therapeutic agents. Unlike other cytokines and IFNs, human IFN-γ does not contain any cysteine and disulfide bonds, which is an unusual feature for a secreted protein [40] . It has been reported that such cysteine residues might stabilize human IFN-γ [41] . Moreover, it is interesting to note that mouse IFN-γ, which contains cysteine residues, presents increased stability when compared with cysteine-free human IFN-γ [42] .
The viral clearance of infected hepatocytes is mediated by CTLs that kill hepatocytes, although virusspecific CTLs can abolish HBV replication without killing infected hepatoytes. Differences between the antiviral and cytotoxic effects of IFN-γ on HBV replication have not been well characterized, but it has been reported that IFN-γ expression can control HBV replication in a non-cytopathic way [8, 12] . IFN-γ mediates its antiviral activity by inducing a reduction of viral genome-containing nucleocapsids; however, the cellular mechanisms involved in the antiviral activity of IFN-γ against HBV have still not been well defined. It has been reported that IFN-γ might regulate the activity of La proteins, thus contributing to the regulation of HBV messenger RNA stability [43] . To activate its antiviral activity, IFN-γ might also require the presence of a proteasome [44] . Studies using HBV transgenic mice have suggested that the antiviral effects of IFN-γ might be mediated by inducible nitric oxide synthase activity [44] , although a recent study of transfected hepatoma cell lines suggested that the antiviral effects of IFN-γ were not dependent on increased inducible nitric oxide synthase production [45] .
In HepG2.2.15 cells treated with S63C or wt IFN-γ, an inhibition of HBV viral replication was observed. This was in line with previous finding that demonstrated a reduction in viral DNA and RNA in HepG2.2.15 cells treated for 4 days with IFN-γ [13] . Furthermore, after heating at 60°C for 10 min, IFN-γ S63C displayed stronger antiviral activity against HBV when compared with wt IFN-γ. These results indicate that the thermostability of S63C IFN-γ is associated with a conservation of its antiviral capacity against HBV replication. We observed a parallel decrease in all replicative intermediate forms found in the nucleocapsid. This was in contrast with previously published data on HBV transduced HepG2 cells that demonstrated a significant reduction of only covalently closed circular and single-stranded forms of HBV DNA [12] . This might reflect differences in the regulation of HBV viral replication between transient and stable HBVexpressing cells.
In conclusion, our results confirm that the activityindependent method constitutes a powerful tool to isolate mutants with increased thermostability but without knowledge of their protein structure [32] . Moreover we have demonstrated that a thermostable S63C IFN-γ variant can sustain its antiviral properties against HBV replication. Our approach to the challenge of prolonging the half-life of human IFN-γ in vivo has potentially broad clinical implications that might provide new opportunities for IFN therapy. These findings suggest that IFN-γ with a capacity for thermostability might achieve more sustained plasma levels following administration in a patient. Finally, this approach might enable a new strategy for the control of HBV replication in patients who have not responded to antiviral therapy.
